Literature DB >> 32844461

Reliability of the Charcot-Marie-Tooth functional outcome measure.

Paula Bray1, Kayla M D Cornett1, Timothy Estilow2,3, Davide Pareyson4, Riccardo Zuccarino5,6, Mariola Skorupinska7, Menelaos Pipis7, Janet E Sowden8, Steven Scherer3, Mary M Reilly7, Michael E Shy5, David N Herrmann8, Joshua Burns1, Katy J Eichinger8.   

Abstract

The CMT-FOM is a 13-item clinical outcome assessment (COA) that measures physical ability in adults with Charcot-Marie-Tooth disease (CMT). Test-retest reliability, internal consistency and convergent validity have been established for the CMT-FOM. This current study sought to establish inter-rater reliability. Following an in-person training of six international clinical evaluators we recruited 10 participants with genetically diagnosed CMT1A, (aged 18-74 years, 6 female). Participants were evaluated using the CMT-FOM over 2 days. Participants were given at least a 3 hour rest between evaluations, and were assessed twice each day. Following the provision of training by master trainers, all 13 items of the CMT-FOM exhibited excellent inter-rater reliability for raw scores (ICC1,1 0.825-0.989) and z-scores (ICC1,1 0.762-0.969). Reliability of the CMT-FOM total score was excellent (ICC1,1 0.983, 95% CI 0.958-0.995). The CMT-FOM is a reliable COA used by clinical evaluators internationally. The next steps are to establish further validation through psychometric evaluation of the CMT-FOM in the Accelerate Clinical Trials in CMT (ACT-CMT) study.
© 2020 Peripheral Nerve Society.

Entities:  

Keywords:  clinical evaluation; clinical outcome assessment; functional measurement; measurement

Year:  2020        PMID: 32844461      PMCID: PMC7520097          DOI: 10.1111/jns.12406

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  16 in total

1.  Genetic and clinical aspects of Charcot-Marie-Tooth's disease.

Authors:  H Skre
Journal:  Clin Genet       Date:  1974       Impact factor: 4.438

2.  Normative reference values for strength and flexibility of 1,000 children and adults.

Authors:  Marnee J McKay; Jennifer N Baldwin; Paulo Ferreira; Milena Simic; Natalie Vanicek; Joshua Burns
Journal:  Neurology       Date:  2016-11-23       Impact factor: 9.910

3.  Reference values for developing responsive functional outcome measures across the lifespan.

Authors:  Marnee J McKay; Jennifer N Baldwin; Paulo Ferreira; Milena Simic; Natalie Vanicek; Joshua Burns
Journal:  Neurology       Date:  2017-03-22       Impact factor: 9.910

4.  Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.

Authors:  Melissa R Mandarakas; Manoj P Menezes; Kristy J Rose; Rosemary Shy; Kate Eichinger; Maria Foscan; Timothy Estilow; Rachel Kennedy; Karen Herbert; Paula Bray; Kathryn Refshauge; Monique M Ryan; Eppie M Yiu; Michelle Farrar; Hugo Sampaio; Isabella Moroni; Emanuela Pagliano; Davide Pareyson; Sabrina W Yum; David N Herrmann; Gyula Acsadi; Michael E Shy; Joshua Burns; Oranee Sanmaneechai
Journal:  Brain       Date:  2018-12-01       Impact factor: 13.501

5.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

Review 6.  Charcot-Marie-Tooth disease.

Authors:  Mary M Reilly; Sinéad M Murphy; Matilde Laurá
Journal:  J Peripher Nerv Syst       Date:  2011-03       Impact factor: 3.494

7.  Reliability of clinical outcome measures in Charcot-Marie-Tooth disease.

Authors:  A Solari; M Laurà; E Salsano; D Radice; D Pareyson
Journal:  Neuromuscul Disord       Date:  2007-10-26       Impact factor: 4.296

Review 8.  Are we prepared for clinical trials in Charcot-Marie-Tooth disease?

Authors:  A M Rossor; M E Shy; M M Reilly
Journal:  Brain Res       Date:  2019-12-30       Impact factor: 3.252

9.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

10.  The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).

Authors:  Katy Eichinger; Joshua Burns; Kayla Cornett; Chelsea Bacon; Mary Lohse Shepherd; Joan Mountain; Janet Sowden; Rosemary Shy; Michael E Shy; David N Herrmann
Journal:  Neurology       Date:  2018-09-19       Impact factor: 9.910

View more
  3 in total

1.  Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A.

Authors:  Katy Eichinger; Janet E Sowden; Joshua Burns; Michael P McDermott; Jeffrey Krischer; John Thornton; Davide Pareyson; Steven S Scherer; Michael E Shy; Mary M Reilly; David N Herrmann
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

2.  Foot Assessment Clinical Scales in Charcot-Marie-Tooth Patients: A Scoping Review.

Authors:  Chiara Rambelli; Davide Mazzoli; Martina Galletti; Giacomo Basini; Paolo Zerbinati; Paolo Prati; Francesca Mascioli; Stefano Masiero; Andrea Merlo
Journal:  Front Hum Neurosci       Date:  2022-06-24       Impact factor: 3.473

Review 3.  Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies.

Authors:  Marina Stavrou; Irene Sargiannidou; Elena Georgiou; Alexia Kagiava; Kleopas A Kleopa
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.